MP47-19 EFFICACY AND SAFETY PROFILE OF TRANSDERMAL TESTOSTERONE FOR HYPOACTIVE SEXUAL DESIRE DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I (MP47)1 May 2024MP47-19 EFFICACY AND SAFETY PROFILE OF TRANSDERMAL TESTOSTERONE FOR HYPOACTIVE SEXUAL DESIRE DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS Jeffrey Song, Gal Saffati, Daniela Rendon, Amit Reddy, Brenna Briles, Madeline Chaput, Nicole Wright, Geneva Pantoja, Bridget Park, David Hinojosa-Gonzalez, Shane Kronstedt, and Mohit Khera Jeffrey SongJeffrey Song , Gal SaffatiGal Saffati , Daniela RendonDaniela Rendon , Amit ReddyAmit Reddy , Brenna BrilesBrenna Briles , Madeline ChaputMadeline Chaput , Nicole WrightNicole Wright , Geneva PantojaGeneva Pantoja , Bridget ParkBridget Park , David Hinojosa-GonzalezDavid Hinojosa-Gonzalez , Shane KronstedtShane Kronstedt , and Mohit KheraMohit Khera View All Author Informationhttps://doi.org/10.1097/01.JU.0001008880.11564.10.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Despite the prevalence of female sexual dysfunction, available treatment options remain limited, leaving many women desperate for solutions. There is limited data on efficacy and safety of testosterone in women. The objective of this study was to evaluate the efficacy of transdermal testosterone in the treatment of hypoactive sexual desire disorder (HSDD) in all women, regardless of menopausal status, and its side effect profile. METHODS: A PROSPERO-registered systemic review of the literature was performed. The Ovid MEDLINE database was searched up to August 13, 2023 for randomized, placebo-controlled trials of transdermal testosterone formulations with adult women with HSDD. We performed a meta-analysis to assess whether efficacy and safety of transdermal testosterone was affected by menopausal type by standardized mean difference (SMD) and odds ratio (OR). RESULTS: We included 9 studies, containing 1476 patients in the testosterone group and 1496 patients in the control group. Use of transdermal testosterone significantly improved libido ratings in postmenopausal women (SMD 0.71, 95% CI 0.62-0.80, p<0.00001), including in subgroup analysis of surgical and natural postmenopausal cohorts (Figure 1). The overall adverse event rates between the testosterone and control groups did not significantly differ (OR 1.05, 95% CI 0.88-1.25, p=0.58), irrespective of subgroup analysis of premenopausal, and surgical and natural postmenopausal cohorts (Figure 2). The most common adverse events were application site reactions and mild androgenic effects of acne and hirsutism. Serious adverse events were rare. CONCLUSIONS: Our analysis highlights the significant and positive impact of transdermal testosterone on libido. This effect was observed across various cohorts, including those who reached menopause naturally or surgically. Our findings also provide valuable insights into the safety profile of transdermal testosterone therapy in this population. Download PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e770 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Jeffrey Song More articles by this author Gal Saffati More articles by this author Daniela Rendon More articles by this author Amit Reddy More articles by this author Brenna Briles More articles by this author Madeline Chaput More articles by this author Nicole Wright More articles by this author Geneva Pantoja More articles by this author Bridget Park More articles by this author David Hinojosa-Gonzalez More articles by this author Shane Kronstedt More articles by this author Mohit Khera More articles by this author Expand All Advertisement PDF downloadLoading ...